Option Found for Retreatment of Chronic Hep C Infection
THURSDAY, Nov. 15, 2018 -- Combined treatment with glecaprevir and pibrentasvir (G/P) is highly effective in treating chronic hepatitis C virus (HCV) genotype-1 infections that failed to respond to direct-acting antiviral therapy, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 15, 2018 Category: Pharmaceuticals Source Type: news

Hepatitis C Treatment Options: 5 Direct Questions
An HCV-infected patient who still injects drugs wants to start direct-acting antiviral therapy. What do guidelines recommend? (Source: ConsultantLive)
Source: ConsultantLive - November 14, 2018 Category: Internal Medicine Authors: Andrew Bowser Tags: Hepatitis C Source Type: news

HCV-Infected Kidney Waitlist Patients: Treat Now or Later? HCV-Infected Kidney Waitlist Patients: Treat Now or Later?
Which factors should be considered in the decision to initiate early or deferred direct-acting antiviral therapy among HCV-positive waitlisted patients?American Journal of Transplantation (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - November 1, 2018 Category: Surgery Tags: Nephrology Journal Article Source Type: news

Direct-acting antiviral therapy for hepatitis  C saves costs in Italy
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2018 Category: Drugs & Pharmacology Source Type: news

Eight Weeks of Antiviral Therapy for Recent HCV Infection Eight Weeks of Antiviral Therapy for Recent HCV Infection
Is an 8-week therapy of paritaprevir/ritonavir/ombitasvir and dasabuvir + ribavirin as effective as the standard 12-week regimen in individuals with recent HCV infection?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 17, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Preemptive DAAs for HCV+ Donor Livers Found Cost Effective
(MedPage Today) -- Direct-acting antiviral therapy in seronegative liver recipients could shorten transplant waiting lists (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - August 24, 2018 Category: Gastroenterology Source Type: news

Recurrence of HCC Following Direct-acting Antiviral Therapy Recurrence of HCC Following Direct-acting Antiviral Therapy
Might direct-acting antivirals increase risk and aggressiveness of hepatocellular carcinoma recurrence? This review aimed to characterize HCC recurrence patterns after DAA therapy.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 23, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Direct Antiviral Therapy of Hep C May Not Boost Hepatocellular-Carcinoma Risk Direct Antiviral Therapy of Hep C May Not Boost Hepatocellular-Carcinoma Risk
Treatment of hepatitis C (HCV) with direct-acting antiviral agents does not appear to increase the risk of hepatocellular carcinoma (HCC) in individuals with cirrhosis, researchers from France report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 3, 2018 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Hep C Expert Interview: Gregory T. Everson, MD
Renowned transplant expert Gregory T. Everson, MD, talked with Patient Care about sensitive issues surrounding liver transplant in the era of direct-acting antiviral therapy. (Source: ConsultantLive)
Source: ConsultantLive - August 1, 2018 Category: Internal Medicine Authors: Andrew D. Bowser Tags: Hepatitis C Source Type: news

HCV: 6 Reasons in Favor of Antiviral Therapy During Pregnancy HCV: 6 Reasons in Favor of Antiviral Therapy During Pregnancy
Dr Nancy Reau discusses factors that could potentially support the use of antiviral therapy during pregnancy to prevent mother-to-child transmission of hepatitis C virus infection.Medscape Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 23, 2018 Category: Consumer Health News Tags: Gastroenterology Commentary Source Type: news

Negative rapid test results may delay antiviral therapy in patients with severe influenza
(American Society for Microbiology) A new study has found that half of influenza cases in patients admitted to the intensive care unit (ICU) received a false negative rapid influenza antigen test (RIAT). The false negative RIAT results could delay antiviral therapy for patients who were in the ICU with severe influenza. The research is presented at ASM Microbe, the American Society for Microbiology's annual meeting, held from June 7-11 in Atlanta, Ga. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 10, 2018 Category: Biology Source Type: news

Liver Stiffness Measurement-Based Approach for HBV Liver Stiffness Measurement-Based Approach for HBV
Decline of liver stiffness from baseline after 1 year of antiviral therapy for HBV infection may reflect remission of liver inflammation and fibrosis.Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 3, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

HBV Treatment Fails to Meet Global Targets (CME/CE)
(MedPage Today) -- Only 5% of hepatitis B patients received antiviral therapy in 2016 (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 26, 2018 Category: Primary Care Source Type: news

Treatment To Prevent Hepatitis C Recurrence After Liver Transplantation
In a clinical trial, researchers found that antiviral therapy prior to a liver transplant can prevent hepatitis C recurrence in some patients. (Source: NIDDK News)
Source: NIDDK News - March 15, 2018 Category: Endocrinology Source Type: news

Hepatitis C Virus Clearance in Older Adults Hepatitis C Virus Clearance in Older Adults
Does HCV clearance with direct-acting antiviral therapy improve outcomes in individuals aged 80 and older--even in the face of severe liver disease and multiple comorbidities?Journal of the American Geriatrics Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 21, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Shortening Duration of Therapy With DAAs for HCV Genotype 1 Shortening Duration of Therapy With DAAs for HCV Genotype 1
Can direct-acting antiviral therapy for hepatitis C genotype 1 be reduced to less than the current standard of 12 weeks without compromising outcomes?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 9, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Sofosbuvir Safe, Effective for HCV in Those With CKD Sofosbuvir Safe, Effective for HCV in Those With CKD
Sofosbuvir-based antiviral therapy cured hepatitis C virus infection in more than 80% of patients with chronic kidney disease, a retrospective cohort study found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 15, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Treating a little-known virus, CMV, to combat hearing loss in children
(University of Utah Health) A National Institutes of Health-supported nationwide clinical trial will test a novel approach to combat hearing loss in children infected by a relatively unknown virus, cytomegalovirus (CMV). The University of Utah Health-led study will determine whether antiviral therapy can halt progressive hearing loss in children with a confirmed CMV infection. CMV is the leading non-genetic cause of hearing loss, contributing from 6 to 30 percent of childhood cases. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 14, 2017 Category: Infectious Diseases Source Type: news

Antiviral Therapy in Patients With Influenza Antiviral Therapy in Patients With Influenza
Which patients should receive antiviral therapy for influenza, and what are the currently available options?U.S. Pharmacist (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 22, 2017 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news

Subcirrhotic Liver Stiffness Cuts HCC Risk in Hepatitis B
Achievement of subcirrhotic range of liver stiffness with antiviral therapy reduces HCC risk (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 10, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Infections, Internal Medicine, Oncology, Journal, Source Type: news

Antiviral therapy is effective in fighting hepatitis C | Letters
The Cochrane analysis casting doubt on this life-saving therapy is flawed and may deter patients from seeking it, say clinicians and scientistsWe are clinicians and scientists who have studied and treated patients with chronic hepatitis C virus infection over many years and patient groups that represent those affected by hepatitis C. We write in response to your article on the effectiveness of antiviral therapy (Hepatitis ‘wonder drug’ may be clinically ineffective, say experts, 9 June). The Cochrane review that you highlight analysed clinical trials, which are by nature short term, where the sole purpose was t...
Source: Guardian Unlimited Science - June 13, 2017 Category: Science Authors: Letters Tags: Hepatitis C Health Pharmaceuticals industry Medical research Drugs Business Science UK news Society Source Type: news

The Potential Role of Polymerase Chain Reaction in Diagnosis of Neonatal Herpes Simplex Virus Infection: Is Viral Culture Outdated?
Even in the era of effective antiviral therapy, neonatal herpes simplex viral infection causes significant morbidity and mortality in newborns. Prompt diagnosis is the cornerstone of treatment of these infants. Outside and inside the neonatal clinical practice, polymerase chain reaction (PCR) is replacing culture as a method of facilitating a speedy diagnosis of herpes simplex virus infection. New pediatric guidelines call for testing of high-risk asymptomatic infants, and thus, many more surface cultures and PCRs are being performed. (Source: Clinical Microbiology Newsletter)
Source: Clinical Microbiology Newsletter - June 6, 2017 Category: Microbiology Authors: Nicole L. Samies, Swathi M. Gowtham Source Type: news

IRE1{alpha} promotes viral infection by conferring resistance to apoptosis
The unfolded protein response (UPR) is an ancient cellular pathway that detects and alleviates protein-folding stresses. The UPR components X-box binding protein 1 (XBP1) and inositol-requiring enzyme 1α (IRE1α) promote type I interferon (IFN) responses. We found that Xbp1-deficient mouse embryonic fibroblasts and macrophages had impaired antiviral resistance. However, this was not because of a defect in type I IFN responses but rather an inability of Xbp1-deficient cells to undergo viral-induced apoptosis. The ability to undergo apoptosis limited infection in wild-type cells. Xbp1-deficient cells were generall...
Source: Signal Transduction Knowledge Environment - June 6, 2017 Category: Science Authors: Fink, S. L., Jayewickreme, T. R., Molony, R. D., Iwawaki, T., Landis, C. S., Lindenbach, B. D., Iwasaki, A. Tags: STKE Research Articles Source Type: news

Risk of HBV Reactivation in Patients on Antivirals for HCV Risk of HBV Reactivation in Patients on Antivirals for HCV
Is there a clinically relevant risk of HBV reactivation during direct-acting antiviral therapy for HCV with an interferon-free regimen?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 23, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

HBIG Plus Antivirals May Prevent HBV Reinfection After Transplant HBIG Plus Antivirals May Prevent HBV Reinfection After Transplant
A very short course of hepatitis B immunoglobulin (HBIG) after liver transplantation, along with long-term antiviral therapy, may prevent hepatitis B virus (HBV) reinfection, a retrospective study suggests.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - May 22, 2017 Category: Transplant Surgery Tags: Transplantation News Source Type: news

Prevalence and Impact of Steatohepatitis in HBV Patients Prevalence and Impact of Steatohepatitis in HBV Patients
This study assessed the prevalence of steatohepatitis in chronic HBV-infected patients, its risk factors, and its correlation with liver fibrosis and response to antiviral therapy.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 9, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C
Dateline City: KENILWORTH, N.J. Findings Presented at The International Liver Congress ™ 2017 Show High Rates of Sustained Virologic Response (SVR12) in Genotype 1 Patients for Whom Direct-Acting Antiviral Therapy Had Previously FailedKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first sustained virologic response1 (SVR) results 12 weeks after completion of therapy (SVR12, considered virologic cure) fromC-SURGE, an ongoing, open label Phase 2 clinical trial evaluating MK-3682B [uprifosbuvir (MK-3682)2/grazoprevir3...
Source: Merck.com - Research and Development News - April 22, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Hepatitis C MSD NYSE:MRK Source Type: news

Hepatitis C treatment can be provided successfully at syringe programme sites
Administering direct-acting antiviral therapy for people who inject drugs at a syringe exchange site led to high sustained response rates in a pilot study in New York City. (Source: PHPartners.org)
Source: PHPartners.org - April 19, 2017 Category: Global & Universal Source Type: news

Poor Adherence to Antiviral Treatment for Hepatitis B Poor Adherence to Antiviral Treatment for Hepatitis B
Antiviral therapy for hepatitis B is effective and improves outcomes, but is often long-term, and adherence can be poor. What factors might influence non-adherence to therapy?Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - February 9, 2017 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news

Scientists crack the structure of HIV machinery
Antiviral therapy could be improved with newly uncovered atomic-level details of the structure of HIV machinery, report researchers. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 5, 2017 Category: Science Source Type: news

Salk scientists crack the structure of HIV machinery
(Salk Institute) Antiviral therapy could be improved with the newly uncovered atomic-level details. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 5, 2017 Category: Biology Source Type: news

Novel Treatment Could Lead to Functional Control of Hep B Novel Treatment Could Lead to Functional Control of Hep B
Nucleic acid polymers block the release of the hepatitis B surface antigen from hepatocytes, boosting the efficacy of standard antiviral therapy, according to an early clinical trial.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 17, 2016 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Costs of HCV greater without antiviral therapy
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 31, 2016 Category: Drugs & Pharmacology Source Type: news

Comparative Effectiveness of HCV Combination Therapies Comparative Effectiveness of HCV Combination Therapies
This analysis compared the efficacy of two commonly used regimens of oral antiviral therapy in a cohort of veterans with hepatitis C.Alimentary Pharmacology & Therapeutics (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 9, 2016 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news

Big step towards cure for HIV and other lifelong viral infections
New research has taken us a step closer to finding a cure for human immunodeficiency virus (HIV), as well as other infections including the glandular fever virus, which is associated with the development of lymphoma. Some infections, such as HIV, cannot be cured with antiviral therapy because the virus effectively hides from the immune system. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 4, 2016 Category: Science Source Type: news

Big step towards cure for lifelong viral infections
(Monash University) New research has taken us a step closer to finding a cure for human immunodeficiency virus (HIV), as well as other infections including the glandular fever virus, which is associated with the development of lymphoma. Some infections, such as HIV, cannot be cured with antiviral therapy because the virus effectively hides from the immune system. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 3, 2016 Category: Global & Universal Source Type: news

Direct Acting Antiviral Therapy After Liver TransplantationDirect Acting Antiviral Therapy After Liver Transplantation
Which direct acting antiviral agents are most effective for patients, and do they help contribute to long-term survival? Current Opinion in Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 22, 2016 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Liver Cancer Found in Hepatitis C Patients on New AntiviralsLiver Cancer Found in Hepatitis C Patients on New Antivirals
For patients infected with chronic hepatitis C virus, there could be a downside to direct-acting antiviral therapy, which has been hailed as a cure. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 15, 2016 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

First Evidence That Hep C Drugs Curb Liver TransplantsFirst Evidence That Hep C Drugs Curb Liver Transplants
Patients are being delisted from liver transplant wait lists because of direct-acting antiviral therapy, investigators report, but there are no long-term data to predict their future, experts caution. Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - April 15, 2016 Category: Transplant Surgery Tags: Gastroenterology News Source Type: news

Antiviral therapy prolongs survival in immune tolerant hepatitis B patients
A new study demonstrates that the use of antiviral therapy for patients in the immune tolerant phase of hepatitis B (HBV) prolongs overall survival and reduces the risk of the most common form of liver cancer (Hepatocellular Carcinoma, HCC) and scarring of the liver (cirrhosis). (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 15, 2016 Category: Science Source Type: news

Antiviral therapy prolongs survival in immune tolerant hepatitis B patients
(European Association for the Study of the Liver) A new study, presented today at The International Liver Congress™ 2016 in Barcelona Spain, demonstrates that the use of antiviral therapy for patients in the immune tolerant phase of hepatitis B (HBV) prolongs overall survival and reduces the risk of the most common form of liver cancer (Hepatocellular Carcinoma, HCC) and scarring of the liver (cirrhosis). (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 15, 2016 Category: Infectious Diseases Source Type: news

Treating patients for hepatitis C could reduce the need for liver transplants
(European Association for the Study of the Liver) A new study presented today demonstrates that patients on the liver transplant list with hepatitis C virus (HCV) and severe liver damage were more likely to be taken off the list or have their need of a liver transplant reduced as a result of direct-acting antiviral therapy. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 14, 2016 Category: Infectious Diseases Source Type: news

Suspected Flu in a High-risk Patient? Don't Delay Antiviral Therapy
The CDC is urging physicians to be more proactive in prescribing antiviral medications for severely ill or high-risk patients in whom flu is suspected or confirmed. (Source: AAFP News)
Source: AAFP News - February 5, 2016 Category: Primary Care Source Type: news

Antiviral Therapy in Chronic Hepatitis EAntiviral Therapy in Chronic Hepatitis E
Does the latest research recommend ribavirin monotherapy as an effective and relatively safe treatment for patients with chronic hepatitis E? Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 11, 2015 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Sofosbuvir and Simeprevir in Liver Transplant RecipientsSofosbuvir and Simeprevir in Liver Transplant Recipients
How safe and effective is combination antiviral therapy in the treatment of recurrent hepatitis C in liver transplant patients? Liver International (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - November 25, 2015 Category: Transplant Surgery Tags: Gastroenterology Journal Article Source Type: news

FDA-approved drug protects mice from Ebola
(University of Iowa Health Care) A new study suggests that gamma interferon, which is an FDA-approved drug, may have potential as an antiviral therapy to prevent Ebola infection when given either before or after exposure to the virus. The University of Iowa study, published Nov. 12 in the journal PLOS Pathogens, found that gamma interferon, given up to 24 hours after exposure, can inhibit Ebola infection in mice and completely protect the animals from death. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 18, 2015 Category: Infectious Diseases Source Type: news

Mechanisms of Non-response to Hepatitis C TherapyMechanisms of Non-response to Hepatitis C Therapy
How does cirrhosis affect the response to antiviral therapy in patients with hepatitis C? Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2015 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

All-oral, DAA options for HCV effective & well tolerated in patients with decompensated cirrhosis
(European Association for the Study of the Liver) Interim data presented today at The International Liver CongressTM 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C is well tolerated and highly effective in patients with decompensated cirrhosis. Sustained virologic response at four weeks was shown to be: sofosbuvir/ribavirin: 75 percent; sofosbuvir/simeprevir: 77 percent; sofosbuvir/simeprevir/ribavirin: 81 percent. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 23, 2015 Category: Biology Source Type: news

Perinatal HBV: Timely Immunoprophylaxis Effective Perinatal HBV: Timely Immunoprophylaxis Effective
Maternal antiviral therapy may be the next step for further decreasing perinatal HBV infections. Medscape Medical News (Source: Medscape ObGyn and Womens Health Headlines)
Source: Medscape ObGyn and Womens Health Headlines - April 21, 2015 Category: OBGYN Tags: Pediatrics News Source Type: news

Researchers Explore Hepatitis B Reactivation in Patients With Rheumatoid Arthritis Treated With Both DMARD and Antiviral Therapy
Source: Lippincott’s Bone and Joint Newsletter - March 20, 2015 Category: Orthopaedics Tags: CME Article Source Type: news